A Phase I, First-in-Human, Open-Label, Dose Escalation Study of LM-102 Injection in Subjects With CLDN18.2-Positive Advanced Solid Tumors
Latest Information Update: 28 Oct 2022
At a glance
- Drugs LM-102 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors LaNova Medicines Limited
- 24 Oct 2022 Status changed from recruiting to discontinued.
- 18 May 2021 Status changed from active, no longer recruiting to recruiting.
- 18 Apr 2021 Status changed from not yet recruiting to active, no longer recruiting.